Tactogen
Growth Stage
Developing new MDMA-like medicines for effective prescription mental wellness
Overview
Raised: $94,542
Total Commitments ($USD)
Platform
Wefunder
Start Date
11/11/2022
Close Date
01/31/2023
Min. Goal
$50,000
Max. Goal
$5,000,000
Min. Investment
$100
Security Type
SAFE
Series
Seed
Funding Type
RegCF
Valuation Cap
$80,000,000
Discount Rate
15%
Rolling Commitments ($USD)
Status
Funded
Reporting Date
02/01/2023
Days Remaining
Funded
% of Min. Goal
189%
% of Max. Goal
2%
Likelihood of Max
Funded
Avg. Daily Raise
$1,167
# of Investors
165
Momentum
Funded
Create a free account today to gain access to KingsCrowd analytics.
Location
Palo Alto, California
Industry
Healthcare & Pharmaceuticals
Tech Sector
HealthTech
Distribution Model
B2B/B2C
Margin
Medium
Capital Intensity
High
Tactogen, with a valuation of $80 million, is raising funds on Wefunder. The company is developing entactogen molecules for effective prescription mental health. Entactogens are MDMA-like molecules that help people embody a better version of themselves and let them keep their fears and self-criticism aside to think clearly about their lives. The aim of Tactogen is to bring the emotional benefits of MDMA to people while warding off their unwanted and off-target effects. Matthew Baggott founded Tactogen in February 2020. The current crowdfunding campaign has a minimum target of $50,000 and a maximum target of $5 million. The campaign proceeds will be used for safety and toxicity studies for leading molecules, Phase 1 clinical trial development, and community initiatives.
Summary Profit and Loss Statement
| Most Recent Year | Prior Year | |
|---|---|---|
|
Revenue |
$0 |
$0 |
|
COGS |
$0 |
$0 |
|
Tax |
$0 |
$0 |
| ||
| ||
|
Net Income |
$-2,483,543 |
$-428,556 |
Summary Balance Sheet
| Most Recent Year | Prior Year | |
|---|---|---|
|
Cash |
$1,784,371 |
$733,443 |
|
Accounts Receivable |
$8,958 |
$0 |
|
Total Assets |
$1,799,821 |
$743,111 |
|
Short-Term Debt |
$136,981 |
$55,689 |
|
Long-Term Debt |
$0 |
$0 |
|
Total Liabilities |
$136,981 |
$55,689 |
Financials as of: 11/11/2022
Create a free account today to gain access to KingsCrowd analytics.
Upgrade to gain access
Pay Monthly
Annually (Save 17%)
-
$12.42 /month
billed annually - Free portfolio tracking and KingsCrowd's quantitative ratings on all raises.
- Plan Includes:
- Everything in Free, plus
- Company specific
KingsCrowd ratings (excluding risk)
- Advanced company search ( with ratings)
- Markets page filters and historical industry data
- Get Edge Annual
Edge
-
$41.58 /month
billed annually - Full site access including KingsCrowd's qualitative analyst reports.
- Plan Includes:
- Everything in Edge, plus
- Full access to detailed Analyst Reports (e.g. Top Deal, Deal to Watch, Neutral, and Underweight)
- Search and filter based on Analyst Reports
- In-depth risk ratings for every raise
- Get Edge Pro Annual
Edge Pro
Already a member? Log in here.
Ratings 
